DrugDashboards

apomorphine hydrocloride

Apomorphine Hydrochloride · APOMORPHINE HYDROCHLORIDE 30 mg/3mL · Injection · Subcutaneous · TruPharma, LLC

NDC 52817-0720-05 · 5 CARTRIDGE in 1 CARTON / 3 mL in 1 CARTRIDGE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. One of its named manufacturing plants, Sharp Sterile Manufacturing, LLC, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$358.70per unit
middle half $328.42$358.70 · 1,606 plans · Apr 1, 2026
Est. net of rebates
≈ $358.70
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
29%of plans cover it
tier 5 · prior auth 88% · step therapy 0% · qty limit 82%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$5,207.85
Reported to Texas DSHS · 2026 annual filing · TruPharma, LLC

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 5 across plans
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA212025
TE code
AP
Approval date
Feb 23, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Apomorphine Hydrochloride (Injection)

LabelerStrengthFirst seenLast seen
MDD US Operations, LLCAPOMORPHINE HYDROCHLORIDE 30 mg/3mLJul 15, 2026Sep 2, 2026
TruPharma, LLCAPOMORPHINE HYDROCHLORIDE 30 mg/3mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "apomorphine hydrocloride — NDC 52817-0720-05," retrieved September 3, 2026, https://drugdashboards.com/drug/52817072005.

Free to cite with attribution — see how the data is put together.